• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Capped RNA primer binding to influenza polymerase and implications for the mechanism of cap-binding inhibitors

tetano

Editor, Senior Moderator
Nucleic Acids Res. 2017 Nov 30. doi: 10.1093/nar/gkx1210. [Epub ahead of print]
[h=1]Capped RNA primer binding to influenza polymerase and implications for the mechanism of cap-binding inhibitors.[/h] Pflug A[SUP]1[/SUP], Gaudon S[SUP]1[/SUP], Resa-Infante P[SUP]1[/SUP], Lethier M[SUP]1[/SUP], Reich S[SUP]1[/SUP], Schulze WM[SUP]1[/SUP], Cusack S[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Influenza polymerase uses short capped primers snatched from nascent Pol II transcripts to initiate transcription of viral mRNAs. Here we describe crystal structures of influenza A and B polymerase bound to a capped primer in a configuration consistent with transcription initiation ('priming state') and show by functional assays that conserved residues from both the PB2 midlink and cap-binding domains are important for positioning the capped RNA. In particular, mutation of PB2 Arg264, which interacts with the triphosphate linkage in the cap, significantly and specifically decreases cap-dependent transcription. We also compare the configuration of the midlink and cap-binding domains in the priming state with their very different relative arrangement (called the 'apo' state) in structures where the potent cap-binding inhibitor VX-787, or a close analogue, is bound. In the 'apo' state the inhibitor makes additional interactions to the midlink domain that increases its affinity beyond that to the cap-binding domain alone. The comparison suggests that the mechanism of resistance of certain mutations that allow virus to escape from VX-787, notably PB2 N510T, can only be rationalized if VX-787 has a dual mode of action, direct inhibition of capped RNA binding as well as stabilization of the transcriptionally inactive 'apo' state.


PMID: 29202182 DOI: 10.1093/nar/gkx1210
 
Back
Top Bottom